Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 13, 2024
Discovery & Translation
Science Spotlight: snoRNA control of protein secretion, plus dual agonists for obesity
BioCentury’s roundup of translational innovations also includes an Arkuda-J&J granulin gene therapy
BioCentury | Jun 21, 2024
Product Development
Rare Disease Spotlight: Rare form of dementia a gateway indication for PGRN?
Half a dozen programs aim to boost PGRN expression in the CNS. They are targeting FTD-GRN as a proving ground
BioCentury | Feb 28, 2024
Emerging Company Profile
Vesper Bio: a sortilin-targeting pill to treat neurological disease
Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia
BioCentury | Nov 19, 2021
Finance
Nov. 18 Quick Takes: RA’s Avilar raises $60M seed for protein degradation tech
Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali
BioCentury | Dec 15, 2020
Deals
Prevail acquisition affords Lilly an ‘entry point’ in gene therapy, with more deals likely to follow
In Prevail, Lilly found an M&A target with expertise in one of its core areas — neuroscience — that can also be a building block around which it expects to amass a gene therapy
BioCentury | Sep 19, 2020
Translation in Brief
Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | Feb 4, 2020
Finance
Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing
BioCentury | Nov 8, 2019
Emerging Company Profile
Arkuda emerges from Atlas with genetic dementia program
Atlas-founded Arkuda debuts with genetically-defined frontotemporal dementia therapy, $44M A round
Items per page:
1 - 10 of 17